Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01158885 · ClinicalTrials.gov registry record · Phase 2
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
A Phase 2 study, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01158885 is a Phase 2 study that was terminated before completion, run by Therapeutic Advances in Childhood Leukemia Consortium. The registered enrollment target is 2 participants.
The verdict
NCT01158885, a Phase 2 study, was terminated before completion, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study will test the ability of clofarabine + cytarabine to eliminate minimal residual disease (MRD) in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) patients whose bone marrows exhibit complete remission by morphology. The toxicity profile of this regimen will be evaluated in addition to toxicity experienced by patients who proceed to stem cell transplant. Overall length of remission will also be collected.
Interventions
- DRUG Methotrexate
- DRUG Clofarabine
- DRUG Intrathecal (IT) Cytarabine
- DRUG Cytarabine intravenous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-10-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01158885
The ClinicalTrials.gov registry entry for NCT01158885 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Methotrexate is the first listed.
NCT01158885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01158885 about?
NCT01158885 is a clinical study titled "Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia". This study will test the ability of clofarabine + cytarabine to eliminate minimal residual disease (MRD) in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) patients whose bone marrows exhibit complete remission by morphology. The toxicity profile of this regimen will be evalu...
What is the current status of trial NCT01158885?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2010-08. Estimated completion is 2012-10-24.
What interventions are being tested in trial NCT01158885?
The interventions under investigation include: Methotrexate (DRUG), Clofarabine (DRUG), Intrathecal (IT) Cytarabine (DRUG), Cytarabine intravenous (DRUG).
Who is sponsoring clinical trial NCT01158885?
This trial is sponsored by Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.